Abstract
Triple negative breast cancer is known for its visceral metastasis. We have found that CXCR4 is overexpressed in triple negative breast cancer and is associated with visceral metastasis. We further investigated whether CXCR4 is a prognostic factor affecting survival following visceral metastasis in breast cancer patients. Our results indicate that increased CXCR4 expression among breast cancer patients with visceral metastasis was positively correlated with poor overall survival (P<0.001). Silencing of CXCR4 was associated with a decrease in the tumorigenic properties of MDA-MB-231 breast cancer cells, caused reversion of EMT and suppression of MMP-9, increased apoptosis, and caused a reduced incidence of tumor lung metastasis in mice. These results are indicative of CXCR4 having a predictive role in patients with visceral metastasis and indicate that shRNA knock down of CXCR4 might be a novel therapeutic strategy to prevent breast cancer metastasis when CXCR4 is overexpressed.
Keywords: Apoptosis, chemokine (C-X-C motif) ligand 12 (CXCL12), CXC chemokine receptor types 4 (CXCR4), EMT (epithelial mesenchymal transition), shRNA, triple negative breast cancer, visceral organ specific metastases.
Current Molecular Medicine
Title:Aberrant Expression of CXCR4 Significantly Contributes to Metastasis and Predicts Poor Clinical Outcome in Breast Cancer
Volume: 14 Issue: 1
Author(s): P. Yang, S.-X. Liang, W.-H. Huang, H.-W. Zhang, X.-L. Li, L.-H. Xie, C.-W. Du and G.-J. Zhang
Affiliation:
Keywords: Apoptosis, chemokine (C-X-C motif) ligand 12 (CXCL12), CXC chemokine receptor types 4 (CXCR4), EMT (epithelial mesenchymal transition), shRNA, triple negative breast cancer, visceral organ specific metastases.
Abstract: Triple negative breast cancer is known for its visceral metastasis. We have found that CXCR4 is overexpressed in triple negative breast cancer and is associated with visceral metastasis. We further investigated whether CXCR4 is a prognostic factor affecting survival following visceral metastasis in breast cancer patients. Our results indicate that increased CXCR4 expression among breast cancer patients with visceral metastasis was positively correlated with poor overall survival (P<0.001). Silencing of CXCR4 was associated with a decrease in the tumorigenic properties of MDA-MB-231 breast cancer cells, caused reversion of EMT and suppression of MMP-9, increased apoptosis, and caused a reduced incidence of tumor lung metastasis in mice. These results are indicative of CXCR4 having a predictive role in patients with visceral metastasis and indicate that shRNA knock down of CXCR4 might be a novel therapeutic strategy to prevent breast cancer metastasis when CXCR4 is overexpressed.
Export Options
About this article
Cite this article as:
Yang P., Liang S.-X., Huang W.-H., Zhang H.-W., Li X.-L., Xie L.-H., Du C.-W. and Zhang G.-J., Aberrant Expression of CXCR4 Significantly Contributes to Metastasis and Predicts Poor Clinical Outcome in Breast Cancer, Current Molecular Medicine 2014; 14 (1) . https://dx.doi.org/10.2174/1566524013666131121115656
DOI https://dx.doi.org/10.2174/1566524013666131121115656 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
Call for Papers in Thematic Issues
Molecular and Cellular Mechanisms in Vertigo / Vestibular Disorders
Vertigo and vestibular diseases are common among middle-aged and older adults, significantly increasing the risk of falls and leading to injuries and disabilities. Despite their prevalence, therapeutic advancements are hindered by a limited understanding of the underlying molecular and cellular mechanisms. This Special Issue is dedicated to bridging this gap ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibition of Human 5-Lipoxygenase and Anti-Neoplastic Effects by 2-Amino-1,4-Benzoquinones
Medicinal Chemistry A Practical Perspective on the Evaluation of Small Molecule CNS Penetration in Drug Discovery
Drug Metabolism Letters Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective
Current Rheumatology Reviews Targeting the Cancer Biomarker CD47: A Review on the Diverse Mechanisms of the CD47 Pathway in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Recent Insights into Osimertinib Analogues against EGFR Positive Non-small Cell Lung Cancer
Current Topics in Medicinal Chemistry Biologics for Extraintestinal Manifestations of IBD
Current Drug Targets Synthesis and Evaluation of 4-arylmethyl Curcumin Analgues as Potent Hsp90 Inhibitors
Letters in Drug Design & Discovery Deregulation of HOX B13 Expression in Urinary Bladder Cancer Progression
Current Medicinal Chemistry Emerging Evidence for Neurotensin Receptor 1 Antagonists as Novel Pharmaceutics in Neurodegenerative Disorders
Mini-Reviews in Medicinal Chemistry A Network-Based Cancer Drug Discovery: From Integrated Multi-Omics Approaches to Precision Medicine
Current Pharmaceutical Design Antimicrobial Activity of Royal Jelly
Anti-Infective Agents Microbial Metabolomics
Current Genomics The Interaction of Zinc Oxide/Green Tea Extract Complex Nanoparticles and its Effect on Monosodium Glutamate Toxicity in Liver of Rats
Current Pharmaceutical Biotechnology Recent Advances in the Analyses of Phytoestrogens and Their Role in Human Health
Current Pharmaceutical Analysis Design and Synthesis of Novel Thiosemicarbazones as Potent Anti-breast Cancer Agents
Letters in Drug Design & Discovery Investigating the Protective Role of Rhodanese Enzyme against Cyanide, the Cytotoxic by-product of Amygdalin, in HDF and L929 Cell Lines
Letters in Drug Design & Discovery Statins: A Conceivable Remedial Role for the Regulation of Cancer Progression
Current Cancer Therapy Reviews Ramifications of m6A Modification on ncRNAs in Cancer
Current Genomics Comprehensive Profiling of Protein Ubiquitination for Drug Discovery
Current Pharmaceutical Design A Critical Appraisal of Lipid Nanoparticles Deployed in Cancer Pharmacotherapy
Recent Advances in Drug Delivery and Formulation